# A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

> **NCT03960502** · PHASE1 · COMPLETED · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Healthy Male Participants

## Interventions

- **DRUG:** AG-881
- **DRUG:** [13C315N3]AG-881

## Key facts

- **NCT ID:** NCT03960502
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-16
- **Primary completion:** 2019-09-07
- **Final completion:** 2019-09-07
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960502, "A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03960502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*